I have been watching MNKD's progress for years. I almost pulled the trigger last year, thank God i did not. BUT in a convenience driven society... where is this product going? With proper marketing mixed with ease of use (compared to the pain of pricking ones self) app driven data...rising diabetes diagnosis worldwide. Afrezza is not going to just disappear. It may languish here for a bit but most importantly we are talking about #1 diabetes, #2 convenience (soon paired with app driven data), #3 an already approved product. GLTA.
Your right its their biggest hurdle and I will be honest it is a difficult task. Its the one reason I didn't get that they didn't leverage social media and other advertising as they need the diabetic community to request it. Tough road to hoe and surely running out of runway based on money. That's why SNY deal should have included equity with a buy out baked into the deal with a set price. Now its a fire sale at $2-$3, take it private or at least find another partner with deep pocket that is willing to take a flyer.
Last year they actually had an offer for 50% at $500M which was foolish not to take at that time. Wrong way management continues to underestimate the task at hand. Well lets see what we get today.
News 
Market Data 
Discover 
